EUVIMEDEUVIMED entdecken
Fallbericht

Nemolizumab for Lichen Amyloidosis With Serial Serum Interleukin‐31 Levels: A Case Report

Tsuyoshi Inoue iD, Wakako Yoshioka, Daisuke Watabe iD, Hiroo Amano iD

The Journal of Dermatology · 2026-06 · 53 (6) · 948-951

DOI: 10.1111/1346-8138.70263 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, online erschienen am 10.04.2026. Verfasst von Tsuyoshi Inoue und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Iwate Medical University, Japan. Hauptthemen laut MEDLINE: Interleukins, Antibodies, Monoclonal, Humanized, Pruritus, Amyloidosis, Familial. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lichen amyloidosis (LA) is a chronic, intensely itchy skin disease that is often difficult to control with conventional therapies. Interleukin‐31 (IL‐31) is an itch‐driving cytokine, and nemolizumab, an antibody to the IL‐31 receptor, has become available for some pruritic dermatoses. We report a man in his 60s with a 6‐year history of treatment‐refractory LA on the trunk and extremities. He received nemolizumab 60 mg subcutaneously every 4 weeks because of persistent severe itch despite topical therapy. Itch intensity improved from 5/10 at baseline to 2/10 at Week 4 and to 1/10 at Week 8, remaining low thereafter. The papular lesions showed marked flattening and regression after five doses, leaving only faint residual pigmentation. Serum IL‐31 concentrations were measured immediately before each injection using a commercial assay. Values decreased after Week 4, reached the lowest level by Week 12 during near‐complete remission, and showed a mild increase by Week 16 without clinical relapse. This case suggests that blocking IL‐31 signaling can rapidly and durably improve severe LA and that repeated serum IL‐31 measurements may help support treatment response over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InterleukinsAntibodies, Monoclonal, HumanizedPruritusAmyloidosis, FamilialSkin Diseases, GeneticHumansMaleMiddle AgedTreatment OutcomeInjections, SubcutaneousSkin

Stichwörter der Autor:innen

amyloidosisinterleukin‐31lichen amyloidosisnemolizumabpruritus

Substanzen

InterleukinsIL31 protein, humanAntibodies, Monoclonal, Humanizednemolizumab

Autor:innen und Institutionen

  • Department of Dermatology, Iwate Medical University, Japan.

ORCID-Profile: Tsuyoshi Inoue, Daisuke Watabe, Hiroo Amano

Zitieren

APA

Inoue, T., Yoshioka, W., Watabe, D., & Amano, H. (2026). Nemolizumab for Lichen Amyloidosis With Serial Serum Interleukin‐31 Levels: A Case Report. The Journal of Dermatology, 53(6), 948-951. https://doi.org/10.1111/1346-8138.70263

Vancouver

Inoue T, Yoshioka W, Watabe D, Amano H. Nemolizumab for Lichen Amyloidosis With Serial Serum Interleukin‐31 Levels: A Case Report. The Journal of Dermatology. 2026;53(6):948-951. doi:10.1111/1346-8138.70263

BibTeX
@article{Inoue2026,
  author = {Inoue, Tsuyoshi and Yoshioka, Wakako and Watabe, Daisuke and Amano, Hiroo},
  title = {Nemolizumab for Lichen Amyloidosis With Serial Serum Interleukin‐31 Levels: A Case Report},
  journal = {The Journal of Dermatology},
  year = {2026},
  volume = {53},
  number = {6},
  pages = {948--951},
  doi = {10.1111/1346-8138.70263}
}
Kostenlos starten →